2m 2m 2m 2m 2m 2m 2m
Biocryst Pharm (BCRX)
NASDAQ
$9.28+$0.14 (+1.49%)
Price as of Jun 23, 2026 6:33 PM EDT- $2.3BMarket Cap
- -7.77%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Biocryst Pharm (BCRX)
$9.28+$0.14 (+1.49%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 623.2M +38.26% | 450.7M +36.00% | 331.4M +22.37% | 270.8M +72.31% | |
Cost of Revenue | 19.1M +55.47% | 12.3M +173.80% | 4.5M -30.07% | 6.4M -11.36% | |
Gross Profit | 604.1M +37.78% | 438.4M +34.11% | 326.9M +23.64% | 264.4M +76.35% | |
Sales and Marketing Expense | 348.6M +31.01% | 266.1M +24.42% | 213.9M +34.21% | 159.4M +34.13% | |
Research and Development Expense | -166.1M -4.87% | -174.6M -19.36% | -216.6M -14.50% | -253.3M +21.31% | |
Depreciation and Amortization Expense | 1.4M +11.48% | 1.2M -24.71% | 1.7M +15.17% | 1.4M +84.94% | |
Total Operating Expenses | 533.8M +17.78% | 453.3M +4.17% | 435.1M +3.78% | 419.3M +25.19% | |
Operating Profit | 341.0M +13,508.93% | -2.5M -97.55% | -103.7M -30.13% | -148.4M -16.48% | |
Interest Income | 10.7M -27.65% | 14.7M N/A | N/A N/A | N/A N/A | |
Interest Expense | -23.3M -41.63% | -39.9M -63.16% | -108.2M +9.23% | -99.1M +67.12% | |
Interest Income and Expense and Net | -12.6M -49.83% | -25.1M -76.78% | -108.2M +9.23% | -99.1M +67.12% | |
Total Nonoperating Income and Expense | -73.6M -12.81% | -84.4M -177.99% | 108.2M +9.23% | 99.1M +67.12% | |
Income before Taxes | 267.4M +407.51% | -87.0M -61.56% | -226.2M -7.43% | -244.4M +34.42% | |
Income Taxes | 3.5M +83.19% | 1.9M +521.61% | 310,000 -88.66% | 2.7M +21.30% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 263.9M +396.87% | -88.9M -60.77% | -226.5M -8.33% | -247.1M +34.26% | |
Net Income from Continuing Operations Applicable to Common | 267.4M +407.51% | -87.0M -61.56% | -226.2M -7.43% | -244.4M +34.42% | |
Basic EPS and Net Income | 1.26 +393.02% | -0.43 -63.56% | -1.18 -11.28% | -1.33 -99.87% | |
Diluted EPS and Net Income | 1.21 +381.40% | -0.43 -63.56% | -1.18 -11.28% | -1.33 -99.87% | |
Basic Weighted Average Shares | 209.9M +1.55% | 206.7M +7.54% | 192.2M +3.38% | 185.9M +3.79% | |
Diluted Weighted Average Shares | 218.6M +5.75% | 206.7M +7.54% | 192.2M +3.38% | 185.9M +3.79% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 89.7M -14.30% | 104.7M -5.36% | 110.6M -63.70% | 304.8M -39.58% | |
Short-Term Investments | 185.0M -14.40% | 216.1M -22.35% | 278.3M +132.84% | 119.5M +3,621.76% | |
Cash and Cash Equivalents and Short-Term Investments | 274.7M -14.37% | 320.9M -17.52% | 389.0M -8.32% | 424.3M -16.41% | |
Total Current Assets | 404.3M -4.18% | 422.0M -14.92% | 496.0M -3.98% | 516.5M -8.77% | |
Accumulated Depreciation | 9.4M -23.93% | 12.3M +10.16% | 11.2M +17.38% | 9.6M +17.71% | |
Property and Plant and Equipment and Net | 8.8M +12.94% | 7.8M -1.68% | 7.9M -8.20% | 8.6M -1.11% | |
Total Long-Term Assets | 5.7M +9.99% | 5.2M -60.59% | 13.1M +92.24% | 6.8M +5.16% | |
Total Assets | 514.2M +4.84% | 490.4M -5.13% | 517.0M -6.01% | 550.0M -6.49% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | 410,000 -84.36% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 196.1M +22.25% | 160.4M +6.93% | 150.0M +42.15% | 105.5M +1.73% | |
Total Long-Term Debt | 0 -100.00% | 314.9M +3.84% | 303.2M +30.92% | 231.6M +70.21% | |
Total Long-Term Liabilities | 8.6M -97.34% | 322.8M +3.59% | 311.6M +31.25% | 237.4M +67.15% | |
Total Liabilities | 633.3M -34.46% | 966.4M +510.16% | 158.4M +42.28% | 111.3M +1.49% | |
Retained Earnings | -1.5B -14.91% | -1.8B +5.29% | -1.7B +15.57% | -1.5B +20.47% | |
Total Stockholders Equity | -119.2M -74.96% | -475.9M +4.48% | -455.5M +54.63% | -294.6M +175.36% | |
Total Shares Outstanding | 213.1M +2.17% | 208.5M +1.35% | 205.8M +9.51% | 187.9M +1.93% | |
Cash Flow | |||||
Cash from Operating Activities | 347.4M +767.76% | -52.0M -45.32% | -95.1M -41.22% | -161.8M +13.85% | |
Capital Expenditures | 2.5M +119.57% | 1.1M -48.15% | 2.2M +60.47% | 1.4M -43.35% | |
Cash from Investing Activities | -13.7M -126.04% | 52.6M +140.00% | -131.5M +2.54% | -128.2M -911.43% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -349.9M +5,974.14% | -5.8M -117.73% | 32.5M -63.10% | 88.0M -75.53% | |
Financials Ratio | |||||
Gross Margin | 96.94% -0.35% | 97.28% -1.39% | 98.65% +1.04% | 97.63% +2.34% | |
Operating Margin | 54.72% +9,798.71% | -0.56% -98.20% | -31.29% -42.90% | -54.81% -51.53% | |
Return on Assets | 52.53% +397.70% | -17.65% -58.45% | -42.46% -2.21% | -43.42% +8.86% | |
Return on Equity | -88.68% -564.68% | 19.08% -68.40% | 60.40% -50.92% | 123.07% -57.79% | |
Revenue Growth | 38.26% +6.28% | 36.00% +60.92% | 22.37% -69.07% | 72.31% -90.76% | |
Current Ratio | 2.06 -21.62% | 2.63 -20.43% | 3.31 -32.45% | 4.90 -10.32% | |
Cash Ratio | 0.46 -29.90% | 0.65 -11.50% | 0.74 -74.46% | 2.89 -40.61% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow